Joanna Su Xian Chong, Fang Ji, Saima Hilal, Joyce Ruifen Chong, Jia Ming Lau, Nathanael Ren Jie Tong, Boon Yeow Tan, Narayanaswamy Venketasubramanian, Mitchell Kim Peng Lai, Christopher Li‐Hsian Chen, Juan Helen Zhou
INTRODUCTIONWe investigated the effects of multiple cerebrovascular disease (CeVD) neuroimaging markers on brain functional connectivity (FC), and how such CeVD‐related FC changes interact with plasma phosphorylated tau (p‐tau)181 (an Alzheimer's disease [AD] marker) to influence downstream neurodegeneration and cognitive changes.METHODSMultivariate associations among four CeVD markers and whole‐brain FC in 529 participants across the dementia spectrum were examined using partial least squares correlation. Interactive effects of CeVD‐related FC patterns and p‐tau181 on longitudinal gray matter volume (GMV) and cognitive changes were investigated using linear mixed‐effects models.RESULTSWe identified a brain FC phenotype associated with high CeVD burden across all markers. Further, expression of this general CeVD‐related FC phenotype and p‐tau181 contributed additively, but not synergistically, to baseline and longitudinal GMV and cognitive changes.DISCUSSIONOur findings suggest that CeVD exerts global effects on the brain connectome and highlight the additive nature of AD and CeVD on neurodegeneration and cognition.HighlightsEffects of multiple cerebrovascular disease (CeVD) markers on functional connectivity were studied.A global network phenotype linked to high burden across CeVD markers was identified.CeVD phenotype and plasma phosphorylated tau 181 contributed additively to downstream outcomes.
引言我们研究了多种脑血管疾病（CeVD）神经影像学标志物对大脑功能连接性（FC）的影响，以及这种与CeVD相关的FC变化如何与血浆磷酸化tau（p-tau）181（一种阿尔茨海默病[AD]标志物）相互作用，从而影响下游神经变性和认知变化.方法使用偏最小二乘法相关性检验了痴呆症谱系中529名参与者的四种CeVD标志物与全脑FC之间的多变量关联。使用线性混合效应模型研究了CeVD相关FC模式和p-tau181对纵向灰质体积（GMV）和认知变化的交互影响。讨论我们的研究结果表明，CeVD 对大脑连接组产生了整体影响，并强调了 AD 和 CeVD 对神经退化和认知的叠加作用。研究发现了一种与高负担CeVD标记物相关的全球网络表型。CeVD表型和血浆磷酸化tau 181对下游结果的影响是叠加的。
{"title":"Additive effects of cerebrovascular disease functional connectome phenotype and plasma p‐tau181 on longitudinal neurodegeneration and cognitive outcomes","authors":"Joanna Su Xian Chong, Fang Ji, Saima Hilal, Joyce Ruifen Chong, Jia Ming Lau, Nathanael Ren Jie Tong, Boon Yeow Tan, Narayanaswamy Venketasubramanian, Mitchell Kim Peng Lai, Christopher Li‐Hsian Chen, Juan Helen Zhou","doi":"10.1002/alz.14328","DOIUrl":"https://doi.org/10.1002/alz.14328","url":null,"abstract":"INTRODUCTIONWe investigated the effects of multiple cerebrovascular disease (CeVD) neuroimaging markers on brain functional connectivity (FC), and how such CeVD‐related FC changes interact with plasma phosphorylated tau (p‐tau)181 (an Alzheimer's disease [AD] marker) to influence downstream neurodegeneration and cognitive changes.METHODSMultivariate associations among four CeVD markers and whole‐brain FC in 529 participants across the dementia spectrum were examined using partial least squares correlation. Interactive effects of CeVD‐related FC patterns and p‐tau181 on longitudinal gray matter volume (GMV) and cognitive changes were investigated using linear mixed‐effects models.RESULTSWe identified a brain FC phenotype associated with high CeVD burden across all markers. Further, expression of this general CeVD‐related FC phenotype and p‐tau181 contributed additively, but not synergistically, to baseline and longitudinal GMV and cognitive changes.DISCUSSIONOur findings suggest that CeVD exerts global effects on the brain connectome and highlight the additive nature of AD and CeVD on neurodegeneration and cognition.Highlights<jats:list list-type=\"bullet\"> <jats:list-item>Effects of multiple cerebrovascular disease (CeVD) markers on functional connectivity were studied.</jats:list-item> <jats:list-item>A global network phenotype linked to high burden across CeVD markers was identified.</jats:list-item> <jats:list-item>CeVD phenotype and plasma phosphorylated tau 181 contributed additively to downstream outcomes.</jats:list-item> </jats:list>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"98 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah Walter, RÍona McArdle, Emily A. Largent, Rebecca Edelmayer, Claire Sexton, Sandra Loyola Sandoval, Helen Medsger, Nancy Meserve, Roland Samaroo, Cynthia Sierra, Marlon M. P. Smeitink, Allison Gibson, Sarah Gregory, Diana Karamacoska, Iracema Leroi, Doris Molina-Henry, Aida Suarez-Gonzalez, Crystal M. Glover
The field of Alzheimer's disease and related dementias (ADRD) urgently requires inclusive research to ensure the priorities and outcomes of research apply to those most impacted. We postulate public and participant involvement (PPI) as a pathway to achieving the best science, both in research that informs health and social policy as well as in therapeutic studies to treat and prevent ADRD. This position paper aims to provide dementia researchers with evidence to understand how to apply PPI. We begin by highlighting the disparities experienced by people with dementia, including ageism, stigma of cognitive impairment, and health disparities for minoritized communities. We then provide examples of PPI in ADRD across the research lifecycle, from defining research topics of priority to those impacted by ADRD, through the design, analysis, dissemination, and translation to policy and practice. We also provide recommendations to create and maintain collaboration between researchers and communities through PPI.
{"title":"Public and participant involvement as a pathway to inclusive dementia research","authors":"Sarah Walter, RÍona McArdle, Emily A. Largent, Rebecca Edelmayer, Claire Sexton, Sandra Loyola Sandoval, Helen Medsger, Nancy Meserve, Roland Samaroo, Cynthia Sierra, Marlon M. P. Smeitink, Allison Gibson, Sarah Gregory, Diana Karamacoska, Iracema Leroi, Doris Molina-Henry, Aida Suarez-Gonzalez, Crystal M. Glover","doi":"10.1002/alz.14350","DOIUrl":"https://doi.org/10.1002/alz.14350","url":null,"abstract":"The field of Alzheimer's disease and related dementias (ADRD) urgently requires inclusive research to ensure the priorities and outcomes of research apply to those most impacted. We postulate public and participant involvement (PPI) as a pathway to achieving the best science, both in research that informs health and social policy as well as in therapeutic studies to treat and prevent ADRD. This position paper aims to provide dementia researchers with evidence to understand how to apply PPI. We begin by highlighting the disparities experienced by people with dementia, including ageism, stigma of cognitive impairment, and health disparities for minoritized communities. We then provide examples of PPI in ADRD across the research lifecycle, from defining research topics of priority to those impacted by ADRD, through the design, analysis, dissemination, and translation to policy and practice. We also provide recommendations to create and maintain collaboration between researchers and communities through PPI.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"11 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shubir Dutt, Davis C. Woodworth, S. Ahmad Sajjadi, Dana E. Greenia, Charles DeCarli, Claudia H. Kawas, María M. Corrada, Daniel A. Nation
In a nested case–control study, we examined how cerebral perfusion relates to cognitive status and amyloid in the oldest-old (i.e., 90 years of age and older).
{"title":"Cerebral perfusion and amyloidosis in the oldest-old","authors":"Shubir Dutt, Davis C. Woodworth, S. Ahmad Sajjadi, Dana E. Greenia, Charles DeCarli, Claudia H. Kawas, María M. Corrada, Daniel A. Nation","doi":"10.1002/alz.14357","DOIUrl":"https://doi.org/10.1002/alz.14357","url":null,"abstract":"In a nested case–control study, we examined how cerebral perfusion relates to cognitive status and amyloid in the oldest-old (i.e., 90 years of age and older).","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"41 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pauline Maillard, Evan Fletcher, Owen Carmichael, Christopher Schwarz, Stephan Seiler, Charles DeCarli
White matter hyperintensities (WMH) and infarcts found on magnetic resonance imaging (MR infarcts) are common biomarkers of cerebrovascular disease. In this review, we summarize the methods, publications, and conclusions stemming from the Alzheimer's Disease Neuroimaging Initiative (ADNI) related to these measures. We combine analysis of WMH and MR infarct data from across the three main ADNI cohorts with a review of existing literature discussing new methodologies and scientific findings derived from these data. Although ADNI inclusion criteria were designed to minimize vascular risk factors and disease, data across all the ADNI cohorts found consistent trends of increasing WMH volumes associated with advancing age, female sex, and cognitive impairment. ADNI, initially proposed as a study to investigate biomarkers of AD pathology, has also helped elucidate the impact of asymptomatic cerebrovascular brain injury on cognition within a cohort relatively free of vascular disease. Future ADNI work will emphasize additional vascular biomarkers.
{"title":"Cerebrovascular markers of WMH and infarcts in ADNI: A historical perspective and future directions","authors":"Pauline Maillard, Evan Fletcher, Owen Carmichael, Christopher Schwarz, Stephan Seiler, Charles DeCarli","doi":"10.1002/alz.14358","DOIUrl":"https://doi.org/10.1002/alz.14358","url":null,"abstract":"White matter hyperintensities (WMH) and infarcts found on magnetic resonance imaging (MR infarcts) are common biomarkers of cerebrovascular disease. In this review, we summarize the methods, publications, and conclusions stemming from the Alzheimer's Disease Neuroimaging Initiative (ADNI) related to these measures. We combine analysis of WMH and MR infarct data from across the three main ADNI cohorts with a review of existing literature discussing new methodologies and scientific findings derived from these data. Although ADNI inclusion criteria were designed to minimize vascular risk factors and disease, data across all the ADNI cohorts found consistent trends of increasing WMH volumes associated with advancing age, female sex, and cognitive impairment. ADNI, initially proposed as a study to investigate biomarkers of AD pathology, has also helped elucidate the impact of asymptomatic cerebrovascular brain injury on cognition within a cohort relatively free of vascular disease. Future ADNI work will emphasize additional vascular biomarkers.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mei Cui, Zishuo Jin, Yingzhe Wang, Jiwei Jiang, Sisi Peng, Qiang Wei, Shuting Zhang, Qingzhang Tuo, Junchao Xie, Haixia Leng, Hongxing Wang, Yanxin Zhao, Peng Lei, Jun Xu, Kai Wang, Junjian Zhang, Yanfeng Jiang, Ding Ding, Fang Xie, Jintai Yu, Qiang Dong
Vascular cognitive impairment (VCI) is highly heterogeneous, with unclear pathogenesis. Individuals with vascular risk factors (VRF), cerebral small vessel disease (CSVD), and stroke are all at risk of developing VCI. To address the growing challenges posed by VCI, the “Vascular, Imaging and Cognition Association of China” (VICA) was established.
{"title":"Imaging, biomarkers, and vascular cognitive impairment in China: Rationale and design for the VICA study","authors":"Mei Cui, Zishuo Jin, Yingzhe Wang, Jiwei Jiang, Sisi Peng, Qiang Wei, Shuting Zhang, Qingzhang Tuo, Junchao Xie, Haixia Leng, Hongxing Wang, Yanxin Zhao, Peng Lei, Jun Xu, Kai Wang, Junjian Zhang, Yanfeng Jiang, Ding Ding, Fang Xie, Jintai Yu, Qiang Dong","doi":"10.1002/alz.14352","DOIUrl":"https://doi.org/10.1002/alz.14352","url":null,"abstract":"Vascular cognitive impairment (VCI) is highly heterogeneous, with unclear pathogenesis. Individuals with vascular risk factors (VRF), cerebral small vessel disease (CSVD), and stroke are all at risk of developing VCI. To address the growing challenges posed by VCI, the “Vascular, Imaging and Cognition Association of China” (VICA) was established.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"10 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eun Hye Lee, Sung Hoon Kang, Daeun Shin, Young Ju Kim, Henrik Zetterberg, Kaj Blennow, Fernando Gonzalez-Ortiz, Nicholas J. Ashton, Bo Kyoung Cheon, Heejin Yoo, Hongki Ham, Jihwan Yun, Jun Pyo Kim, Hee Jin Kim, Duk L. Na, Hyemin Jang, Sang Won Seo
We aimed to investigate which factors affect plasma biomarker levels via amyloid beta (Aβ)-independent or Aβ-dependent effects and improve the predictive performance of these biomarkers for Aβ positivity on positron emission tomography (PET).
{"title":"Plasma Alzheimer's disease biomarker variability: Amyloid-independent and amyloid-dependent factors","authors":"Eun Hye Lee, Sung Hoon Kang, Daeun Shin, Young Ju Kim, Henrik Zetterberg, Kaj Blennow, Fernando Gonzalez-Ortiz, Nicholas J. Ashton, Bo Kyoung Cheon, Heejin Yoo, Hongki Ham, Jihwan Yun, Jun Pyo Kim, Hee Jin Kim, Duk L. Na, Hyemin Jang, Sang Won Seo","doi":"10.1002/alz.14368","DOIUrl":"https://doi.org/10.1002/alz.14368","url":null,"abstract":"We aimed to investigate which factors affect plasma biomarker levels via amyloid beta (Aβ)-independent or Aβ-dependent effects and improve the predictive performance of these biomarkers for Aβ positivity on positron emission tomography (PET).","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"159 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fatemeh Seifar, Edward J. Fox, Anantharaman Shantaraman, Yue Liu, Eric B. Dammer, Erica Modeste, Duc M. Duong, Luming Yin, Adam N. Trautwig, Qi Guo, Kaiming Xu, Lingyan Ping, Joseph S. Reddy, Mariet Allen, Zachary Quicksall, Laura Heath, Jo Scanlan, Erming Wang, Minghui Wang, Abby Vander Linden, William Poehlman, Xianfeng Chen, Saurabh Baheti, Charlotte Ho, Thuy Nguyen, Geovanna Yepez, Adriana O. Mitchell, Stephanie R. Oatman, Xue Wang, Minerva M. Carrasquillo, Alexi Runnels, Thomas Beach, Geidy E. Serrano, Dennis W. Dickson, Edward B. Lee, Todd E. Golde, Stefan Prokop, Lisa L. Barnes, Bin Zhang, Varham Haroutunian, Marla Gearing, James. J Lah, Philip De Jager, David A Bennett, Anna Greenwood, Nilüfer Ertekin-Taner, Allan I. Levey, Aliza Wingo, Thomas Wingo, Nicholas T. Seyfried
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within non-Hispanic White (NHW) populations. Here we provide an extensive survey of the proteomic landscape of AD across diverse racial/ethnic groups.
{"title":"Large-scale deep proteomic analysis in Alzheimer's disease brain regions across race and ethnicity","authors":"Fatemeh Seifar, Edward J. Fox, Anantharaman Shantaraman, Yue Liu, Eric B. Dammer, Erica Modeste, Duc M. Duong, Luming Yin, Adam N. Trautwig, Qi Guo, Kaiming Xu, Lingyan Ping, Joseph S. Reddy, Mariet Allen, Zachary Quicksall, Laura Heath, Jo Scanlan, Erming Wang, Minghui Wang, Abby Vander Linden, William Poehlman, Xianfeng Chen, Saurabh Baheti, Charlotte Ho, Thuy Nguyen, Geovanna Yepez, Adriana O. Mitchell, Stephanie R. Oatman, Xue Wang, Minerva M. Carrasquillo, Alexi Runnels, Thomas Beach, Geidy E. Serrano, Dennis W. Dickson, Edward B. Lee, Todd E. Golde, Stefan Prokop, Lisa L. Barnes, Bin Zhang, Varham Haroutunian, Marla Gearing, James. J Lah, Philip De Jager, David A Bennett, Anna Greenwood, Nilüfer Ertekin-Taner, Allan I. Levey, Aliza Wingo, Thomas Wingo, Nicholas T. Seyfried","doi":"10.1002/alz.14360","DOIUrl":"https://doi.org/10.1002/alz.14360","url":null,"abstract":"Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within non-Hispanic White (NHW) populations. Here we provide an extensive survey of the proteomic landscape of AD across diverse racial/ethnic groups.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"76 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anna H. Boerwinkle, Julie K. Wisch, Benjamin L. Handen, Elizabeth Head, Mark Mapstone, Michael S. Rafii, Sid E. O'Bryant, Sharon J. Krinsky-McHale, Florence Lai, H. Diana Rosas, Shahid Zaman, Ira T. Lott, Dana Tudorascu, Matthew Zammit, Adam M. Brickman, Joseph H. Lee, Beau M. Ances
Development of Alzheimer's disease (AD) pathology in Down's syndrome (DS) occurs within a compressed timeline compared to sporadic or other genetic forms of AD.
{"title":"The mediating role of plasma glial fibrillary acidic protein in amyloid and tau pathology in Down's syndrome","authors":"Anna H. Boerwinkle, Julie K. Wisch, Benjamin L. Handen, Elizabeth Head, Mark Mapstone, Michael S. Rafii, Sid E. O'Bryant, Sharon J. Krinsky-McHale, Florence Lai, H. Diana Rosas, Shahid Zaman, Ira T. Lott, Dana Tudorascu, Matthew Zammit, Adam M. Brickman, Joseph H. Lee, Beau M. Ances","doi":"10.1002/alz.14359","DOIUrl":"https://doi.org/10.1002/alz.14359","url":null,"abstract":"Development of Alzheimer's disease (AD) pathology in Down's syndrome (DS) occurs within a compressed timeline compared to sporadic or other genetic forms of AD.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"95 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karen Nuytemans, Sanne Franzen, Iris J. Broce, Paulo Caramelli, Ratnavalli Ellajosyula, Elizabeth Finger, Veer Gupta, Vivek Gupta, Ignacio Illán-Gala, Samantha M. Loi, Darby Morhardt, Yolande Pijnenburg, Katya Rascovsky, Monique M. Williams, Jennifer S. Yokoyama, Juliana Acosta-Uribe, Rufus Akinyemi, Suvarna Alladi, Biniyam A. Ayele, Yavuz Ayhan, Renelle Bourdage, Sheila Castro-Suarez, Leonardo Cruz de Souza, Penny Dacks, Sterre C. M. de Boer, Jessica de Leon, Shana Dodge, Stephanie Grasso, Nupur Ghoshal, Vidyulata Kamath, Fiona Kumfor, Jordi A. Matias-Guiu, Pauline Narme, T. Rune Nielsen, Daniel Okhuevbie, Stefanie Piña-Escudero, Ramiro Ruiz-Garcia, Brigid Ryan, Marta Scarioni, Andrea Slachevsky, Aida Suarez-Gonzalez, Boon Lead Tee, Elena Tsoy, Hulya Ulugut, Chiadi U. Onyike, Ganesh M. Babulal
Frontotemporal dementia (FTD) is one of the leading causes of young-onset dementia before age 65, typically manifesting as abnormal behavior (in behavioral variant FTD) or language impairment (in primary progressive aphasia). Although FTD affects all populations across the globe, knowledge regarding the pathophysiology and genetics derives primarily from studies conducted in North America and Western Europe. Globally, biomedical research for FTD is hindered by variable access to diagnosis, discussed in this group's earlier article, and by reduced access to expertise, funding, and infrastructure. This perspective paper was produced by two professional interest areas of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) and discusses the field's current status on the cross-cultural aspects of basic and translational research in FTD (including that focused on epidemiology, genetics, biomarkers, and treatment). It subsequently provides a summary of gaps and needs to address the disparities and advance global FTD biomedical research.
{"title":"Gaps in biomedical research in frontotemporal dementia: A call for diversity and disparities focused research","authors":"Karen Nuytemans, Sanne Franzen, Iris J. Broce, Paulo Caramelli, Ratnavalli Ellajosyula, Elizabeth Finger, Veer Gupta, Vivek Gupta, Ignacio Illán-Gala, Samantha M. Loi, Darby Morhardt, Yolande Pijnenburg, Katya Rascovsky, Monique M. Williams, Jennifer S. Yokoyama, Juliana Acosta-Uribe, Rufus Akinyemi, Suvarna Alladi, Biniyam A. Ayele, Yavuz Ayhan, Renelle Bourdage, Sheila Castro-Suarez, Leonardo Cruz de Souza, Penny Dacks, Sterre C. M. de Boer, Jessica de Leon, Shana Dodge, Stephanie Grasso, Nupur Ghoshal, Vidyulata Kamath, Fiona Kumfor, Jordi A. Matias-Guiu, Pauline Narme, T. Rune Nielsen, Daniel Okhuevbie, Stefanie Piña-Escudero, Ramiro Ruiz-Garcia, Brigid Ryan, Marta Scarioni, Andrea Slachevsky, Aida Suarez-Gonzalez, Boon Lead Tee, Elena Tsoy, Hulya Ulugut, Chiadi U. Onyike, Ganesh M. Babulal","doi":"10.1002/alz.14312","DOIUrl":"https://doi.org/10.1002/alz.14312","url":null,"abstract":"Frontotemporal dementia (FTD) is one of the leading causes of young-onset dementia before age 65, typically manifesting as abnormal behavior (in behavioral variant FTD) or language impairment (in primary progressive aphasia). Although FTD affects all populations across the globe, knowledge regarding the pathophysiology and genetics derives primarily from studies conducted in North America and Western Europe. Globally, biomedical research for FTD is hindered by variable access to diagnosis, discussed in this group's earlier article, and by reduced access to expertise, funding, and infrastructure. This perspective paper was produced by two professional interest areas of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) and discusses the field's current status on the cross-cultural aspects of basic and translational research in FTD (including that focused on epidemiology, genetics, biomarkers, and treatment). It subsequently provides a summary of gaps and needs to address the disparities and advance global FTD biomedical research.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"41 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rachel L. Nosheny, Melanie Miller, Catherine Conti, Derek Flenniken, Miriam Ashford, Adam Diaz, Juliet Fockler, Diana Truran, Winnie Kwang, Shaveta Kanoria, Dallas Veitch, Robert C. Green, Michael W. Weiner
The Alzheimer's Disease Neuroimaging Initiative (ADNI) Administrative Core oversees and coordinates all ADNI activities, to ensure the success and maximize the impact of ADNI in advancing Alzheimer's disease (AD) research and clinical trials. It manages finances and develops policies for data sharing, publications using ADNI data, and access to ADNI biospecimens. The Core develops and executes pilot projects to guide future ADNI activities and identifies key innovative methods for inclusion in ADNI. For ADNI4, the Administrative Core collaborates with the Engagement, Clinical, and Biomarker Cores to develop and evaluate novel, digital methods and infrastructure for participant recruitment, screening, and assessment of participants. The goal of these efforts is to enroll 500 participants, including > 50% from underrepresented populations, 40% with mild cognitive impairment, and 80% with elevated AD biomarkers. This new approach also provides a unique opportunity to validate novel methods.
{"title":"The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials","authors":"Rachel L. Nosheny, Melanie Miller, Catherine Conti, Derek Flenniken, Miriam Ashford, Adam Diaz, Juliet Fockler, Diana Truran, Winnie Kwang, Shaveta Kanoria, Dallas Veitch, Robert C. Green, Michael W. Weiner","doi":"10.1002/alz.14311","DOIUrl":"https://doi.org/10.1002/alz.14311","url":null,"abstract":"The Alzheimer's Disease Neuroimaging Initiative (ADNI) Administrative Core oversees and coordinates all ADNI activities, to ensure the success and maximize the impact of ADNI in advancing Alzheimer's disease (AD) research and clinical trials. It manages finances and develops policies for data sharing, publications using ADNI data, and access to ADNI biospecimens. The Core develops and executes pilot projects to guide future ADNI activities and identifies key innovative methods for inclusion in ADNI. For ADNI4, the Administrative Core collaborates with the Engagement, Clinical, and Biomarker Cores to develop and evaluate novel, digital methods and infrastructure for participant recruitment, screening, and assessment of participants. The goal of these efforts is to enroll 500 participants, including > 50% from underrepresented populations, 40% with mild cognitive impairment, and 80% with elevated AD biomarkers. This new approach also provides a unique opportunity to validate novel methods.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"11 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：